A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families

Human Mutation

Volumn 20, Issue 5, 2002, Pages 352-357

  Phelan, Catherine M ^a   Kwan, Elaine ^a   Jack, Elaine ^a   Li, Song ^a   Morgan, Cindy ^a   Aubé, Jennifer ^a   Hanna, Danielle ^a   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ashkenazi Jews; BRCA1; Breast cancer; Non founder mutation; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER FAMILY; CODOMINANCE; CONTROLLED STUDY; ETHNOLOGY; EXON; FEMALE; FOUNDER EFFECT; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; JEW; MAJOR CLINICAL STUDY; MISSENSE MUTATION; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; FOUNDER EFFECT; GENE FREQUENCY; GENES, BRCA1; HUMANS; JEWS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; PEDIGREE;

EID: 0036409453     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10123     Document Type: Article

References (26)

1. Abeliovich D, Kaduri L, Wang T, Salame D, Lerer I, Sagi M, Gueta TZ, Peretz T 1999. Mutation analysis in BRCA1 and BRCA2 genes in breast cancer Jewish patients non-carriers of the Ashkenazi founder mutations. In: Proceedings of the 13th BCLC General Meeting, Amsterdam, Nov. 1999. Abstract A6.
2. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. 1996. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 58:1166-1176.
3. BIC Database: www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/Member/index.html. NHGRI, Bethesda, MD.
4. Frank TS, Gumpper KL, Manley SA, Ward BE. 1998. The proportion of atypical protein-truncating mutations in BRCA1 and BRCA2 in women of Ashkenazi ancestry. Br Cancer Res Treatment 50:296.
5. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. 2002. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490.
6. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. 1995. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 57:1284-1297.
7. Ganguly T, Dhulipala R, Goldmilow L, Ganguly A. 1998. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Hum Genet 102:549-556.
8. Hadjisavvas A, Adamou A, O'Dowd Phanis C, Todd CM, Kitsios P, Kyriacou K, Christodoulou CG. 2002. Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family. Oncol Rep 9:383-386.
9. Halle D, Catane R, Kaufman B. 1998. A new BRCA2 mutation in Ashkenazi and non-Ashkenazi Jewish patients: Another founder mutation? In: Proceedings of the AACR Annual Meeting, New Orleans, 1998.
10. Hu YF, Miyake T, Ye Q, Li R. 2000. Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. J Biol Chem 275:40910-40915.
11. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K. 2002. Incidence of non-founder BRCA1 and BRCA2 mutations in high-risk Ashkenazi breast and ovarian families. J Med Genet 39:611-614.
12. Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J, Narod SA. 2000. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet 57:213-220.
13. Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger, Stadler J, Gutman H, Abeliovich D. 1998. The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272-274.
14. Liede A, Karlan B, Baldwin RL, Platt L, Kuperstein G, Narod SA. 2002. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Onc 20:1570-1577.
15. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA. 2000. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259-1272.
16. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitz J, King MC, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA, Goldgar D. 1998. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study. Am J Hum Genet 62:1381-1388.
17. Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. 1998. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol 70:432-434.
18. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC. 1997. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031-1040.
19. Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E. 2000. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat 16:491-501.
20. Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E. 2001. The Tyr978X BRCA1 mutation in non-Ashkenazi Jews: Occurrence in high-risk families, general population and unselected ovarian cancer patients. Community Genet 4:50-55.
21. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408.
22. Theodor L, Bar-Sade R, Kruglikova A, Ben-Baruch G, Risel S, Shiri-Sverdlov R, Hirsh Yechezkel G, Modan B, Papa MZ, Rechavi G, Friedman E. 1998. An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews. Br J Cancer 77:1880-1883.
23. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE. 1996. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183.
24. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Ghadirian P, Narod SA. 1998. Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families. Am J Hum Genet 63:1341-1351.
25. van Orsouw NJ, Dhanda RK, Elhaji Y, Narod SA, Li FP, Eng C, Vijg J. 1999. A highly accurate, low cost test for BRCA1 mutations. J Med Genet 36:747-753.
26. Warner E, Foulkes WD, Goodwin P, Meschino W, Blondal J, Paterson C, Ozlecik H, Goss P, Allingham-Hawkins D, Hamel N, di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet J-S, Narod S. 1999. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1241-1247.